Drug Trial Radar · NCT07793942
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Sep 26, 2028
Study completion Jul 28, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery. In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer. The goals of this trial are to learn: * About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems. * How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.
Conditions
- Malignant Neoplam
- Advanced Solid Tumors
Interventions
MK-2010Biological
Administered as an intravenous (IV) infusion.
PembrolizumabBiological
Administered intravenously as 400 mg every 6 weeks.
5-FluorouracilDrug
Administered intravenously per approved product label.
Leucovorin or LevoleucovorinDrug
Administered intravenously per approved product label.
OxaliplatinDrug
Administered intravenously per approved product label.
BelzutifanDrug
Administered orally as 120 mg daily.
GemcitabineDrug
Administered intravenously per approved product label.
CisplatinDrug
Administered intravenously per approved product label.
CarboplatinDrug
Administered intravenously per approved product label.
PaclitaxelDrug
Administered intravenously per approved product label.
Nab-paclitaxelDrug
Administered intravenously per approved product label.
PemetrexedDrug
Administered intravenously per approved product label.
EpinephrineDrug
Administered per approved product label as rescue medication.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 24 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
- Number of Participants Who Experience Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
- Objective Response Rate (ORR)Time frame: Up to approximately 24 months
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
New Jersey Cancer Care ( Site 7002)
Belleville, New Jersey · Recruiting
START Astera, LLC ( Site 0220)
East Brunswick, New Jersey · Recruiting
Taylor Cancer Research Center ( Site 9500)
Maumee, Ohio · Recruiting
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)
Eugene, Oregon · Recruiting
Princess Margaret Cancer Centre ( Site 1400)
Toronto, Ontario, Canada · Recruiting
Cantonal Hospital St.Gallen ( Site 1100)
Sankt Gallen, Canton of St. Gallen, Switzerland · Recruiting
CHUV (centre hospitalier universitaire vaudois) ( Site 1101)
Lausanne, Canton of Vaud, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.